TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12455569

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) therapy 6,000 U/week for 6 months
Number of subjects: 22
Study: 10510547

Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 50
Study: 8750052

Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 90
Study: 1844569

Group type: EXPERIMENTAL
Intervention: ATP‐E supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7023744

Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 232

Group type: COMPARATOR
Intervention: hydralazine
Number of subjects: 232
Study: 31589891

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 30673911

Group type: EXPERIMENTAL
Intervention: Teacher ratings on the Adaptive Behavior Assessment System (ABAS)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Parent ratings on the Adaptive Behavior Assessment System (ABAS)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Correlation between parent and teacher scores
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Parent-teacher agreement analysis
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Moderators of difference scores
Number of subjects: 103
Study: 28729329

Group type: EXPERIMENTAL
Intervention: Low chloride fluid strategy
Number of subjects: 100

Group type: COMPARATOR
Intervention: High chloride fluid strategy
Number of subjects: 100
Study: 25040164

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Food supplementation (FS)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation + Food supplementation (PS+FS)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Clinic control (CC)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Hospital control (CH)
Number of subjects: 507
Study: 23487539

Group type: EXPERIMENTAL
Intervention: CCL21 levels measured at randomization
Number of subjects: 2601
Study: 21652290

Group type: EXPERIMENTAL
Intervention: Chimney stove
Number of subjects: 266

Group type: COMPARATOR
Intervention: Open fire
Number of subjects: 266
Study: 19552017

Group type: EXPERIMENTAL
Intervention: Diclofenac and famotidin
Number of subjects: 224

Group type: COMPARATOR
Intervention: Diclofenac only
Number of subjects: 224
Study: 17785672

Group type: EXPERIMENTAL
Intervention: Brivaracetam 10, 20, 40, or 80 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Brivaracetam 80 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 18
Study: 15553820

Group type: EXPERIMENTAL
Intervention: bushen tiaogan qingxin recipe (BTQR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: hormone replacement therapy (HRT)
Number of subjects: 40
Study: 11684374

Group type: EXPERIMENTAL
Intervention: Calisthenic home exercises
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 137
Study: 10207795

Group type: EXPERIMENTAL
Intervention: Interferon therapy (10 MU/m2 of lymphoblastoid interferon alfa 3 times per week for 12 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45
Study: 8998405

Group type: EXPERIMENTAL
Intervention: Physical stress stimuli
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Psychological stress stimuli
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control session (no stress stimulus)
Number of subjects: 18
Study: 2205259

Group type: EXPERIMENTAL
Intervention: Combination of 5-fluorouracil (5-FU) and plasma perfusion (PP) over protein A-Sepharose (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination of 5-FU and PP over sepharose (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5-FU alone (group C)
Number of subjects: 30
Study: 118024

Group type: EXPERIMENTAL
Intervention: Corn oil diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Palm oil diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 12
Study: 31634603

Group type: EXPERIMENTAL
Intervention: Pharmacomechanical therapy
Number of subjects: 97
Study: 29733435

Group type: EXPERIMENTAL
Intervention: Imarikiren 80 mg (nonelderly)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Imarikiren 160 mg (nonelderly)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Imarikiren 80 mg (elderly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26872902

Group type: EXPERIMENTAL
Intervention: Intra-operative specimen mammography (ISM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard specimen mammography (SSM)
Number of subjects: 72
Study: 24886163

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Volumetric arc therapy (VMAT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Tomotherapy (TOMO)
Number of subjects: 5
Study: 23118533

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy plus inspiratory muscle training (IMT) with a Threshold IMT(®) device
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 28
Study: 20975107

Group type: EXPERIMENTAL
Intervention: Dextrose meal (2.25 g/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Maltodextrin meal (2.25 g/kg)
Number of subjects: 10
Study: 17935636

Group type: EXPERIMENTAL
Intervention: Orientation statement letter delivered 24-48 h before the first appointment
Number of subjects: 764

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 764
Study: 15790438

Group type: COMPARATOR
Intervention: Paclitaxel + Carboplatin (PC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin + Amifostine (PC + A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 90
Study: 14634942

Group type: EXPERIMENTAL
Intervention: 4 mL bupivacaine 0.5%
Number of subjects: 29

Group type: COMPARATOR
Intervention: 4 mL saline 0.9%
Number of subjects: 29
Study: 10390665

Group type: EXPERIMENTAL
Intervention: granisetron 40 mg kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: perphenazine 70 mg kg‐1
Number of subjects: 90
Study: 8877766

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside 5'‐monophosphate (ARA‐AMP), 5 mg/kg/day during 7 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lymphoblastoid interferon (ly‐IFN), 5,000,000 units, three times per week, during 4 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lymphoblastoid interferon (ly‐IFN)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside 5'‐monophosphate (ARA‐AMP)
Number of subjects: 20
Study: 1611974

Group type: EXPERIMENTAL
Intervention: Local anaesthesia nerve blocks in the pterygomandibular space
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Partial nerve resection and microsurgical reconstruction
Number of subjects: 506
Study: 6357595

Group type: EXPERIMENTAL
Intervention: 600 mg epirizole for 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: 3000 mg ASA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg epirizole
Number of subjects: 10
Study: 2859465

Group type: EXPERIMENTAL
Intervention: Calcium bis acetyl homotaurine (Ca AOTA, 25 mg/kg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 31088531

Group type: EXPERIMENTAL
Intervention: Video intervention therapy (VIT) consisting of four modules with one video-recorded play session and one VIT session per week.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual plus weekly play sessions (Control group).
Number of subjects: 0
Study: 29976251

Group type: EXPERIMENTAL
Intervention: Individual or combined water, sanitation, handwashing, and nutrition interventions
Number of subjects: 5551

Group type: EXPERIMENTAL
Intervention: Handwashing interventions
Number of subjects: 5551

Group type: EXPERIMENTAL
Intervention: Water intervention arms
Number of subjects: 5551

Group type: EXPERIMENTAL
Intervention: Nutrition arms
Number of subjects: 5551

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5551
Study: 26859512

Group type: EXPERIMENTAL
Intervention: NCPAP via binasal prongs (NP)
Number of subjects: 149

Group type: COMPARATOR
Intervention: NCPAP via nasal mask (NM)
Number of subjects: 149
Study: 24617745

Group type: EXPERIMENTAL
Intervention: Parent-adolescent family functioning discrepancies
Number of subjects: 746
Study: 22482940

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (3 mg/m² on days 1, 4, and 7 during induction and day 1 of each of the two consolidation chemotherapy courses)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control
Number of subjects: 280
Study: 20630463

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 44
Study: 18929703

Group type: EXPERIMENTAL
Intervention: Aggressive lovastatin treatment (LDL cholesterol target <85 mg/dl)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Moderate lovastatin treatment (LDL cholesterol target <140 mg/dl)
Number of subjects: 1116
Study: 16029263

Group type: EXPERIMENTAL
Intervention: Axial length measurement
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Refraction measurement
Number of subjects: 663

Group type: COMPARATOR
Intervention: Comparison of different ARM stages
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Sex differences in axial length and refraction
Number of subjects: 663
Study: 14644225

Group type: EXPERIMENTAL
Intervention: Mouse EVES with HMD viewing
Number of subjects: 70

Group type: COMPARATOR
Intervention: Optical magnifier
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All EVES
Number of subjects: 70
Study: 10873108

Group type: EXPERIMENTAL
Intervention: BIS-1 with OKT3 activation for 72 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OKT3 activation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBS, interleukin-2, OKT3, or interleukin-2/OKT3 for T-cell activation
Number of subjects: 0
Study: 8641743

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1298186

Group type: EXPERIMENTAL
Intervention: SIN-1 (1 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (5 mg)
Number of subjects: 12
Study: 6237916

Group type: EXPERIMENTAL
Intervention: Nicorandil 15 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicorandil 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicorandil 60 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30613065

Group type: EXPERIMENTAL
Intervention: Rituximab plus glucocorticoid (GC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avacopan (CCX168)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study: 30375699

Group type: EXPERIMENTAL
Intervention: Quetiapine plus lamotrigine
Number of subjects: 201

Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 201

Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 27009317

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy skills training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation training (supportive discussion and instruction)
Number of subjects: 0
Study: 25153504

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation for CD strictures
Number of subjects: 90

Group type: COMPARATOR
Intervention: Endoscopic balloon dilation for non-CD strictures
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation for both groups
Number of subjects: 90
Study: 22302565

Group type: EXPERIMENTAL
Intervention: Physical control measures
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both chemical (tannic acid) and physical interventions
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Chemical intervention (tannic acid)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study: 19793859

Group type: EXPERIMENTAL
Intervention: Carbohydrate energy supplementation (15,058 +/- 6211 kcal over 21 days, >6 kcal x kg(‐1) x d(‐1))
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 41
Study: 17150247

Group type: EXPERIMENTAL
Intervention: Doxorubicin and cisplatin treatment in Stage III/IV patients with BMI ≥ 40
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Doxorubicin and cisplatin treatment in patients with higher BMI
Number of subjects: 949

Group type: COMPARATOR
Intervention: Doxorubicin and cisplatin treatment
Number of subjects: 949
Study: 16398437

Group type: EXPERIMENTAL
Intervention: Acupoint electro-superconducting therapy with Chinese herbal drugs contained pad
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo pad
Number of subjects: 60
Study: 12480356

Group type: EXPERIMENTAL
Intervention: 10 mg single-dose mifepristone
Number of subjects: 4136

Group type: EXPERIMENTAL
Intervention: 1.5 mg single-dose levonorgestrel
Number of subjects: 4136

Group type: EXPERIMENTAL
Intervention: Two doses of 0.75 mg levonorgestrel given 12 hours apart
Number of subjects: 4136

Group type: COMPARATOR
Intervention: Levonorgestrel (the two regimens combined)
Number of subjects: 4136
Study: 10375949

Group type: EXPERIMENTAL
Intervention: Motor efficiency examination in patients with CSPS
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Range of active movements
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Strength of muscle groups
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Motor efficiency parameters
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Motor efficiency examinations
Number of subjects: 71
Study: 8970267

Group type: EXPERIMENTAL
Intervention: 6-week training intervention
Number of subjects: 109
Study: 2003792

Group type: EXPERIMENTAL
Intervention: Topical 0.01% dexamethasone sodium phosphate drops
Number of subjects: 12

Group type: COMPARATOR
Intervention: Artificial tears alone (Control)
Number of subjects: 12
Study: 6722395

Group type: EXPERIMENTAL
Intervention: Apomorphine (0.75 mg s.c.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30733966

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Sham-acupuncture (SA)
Number of subjects: 822
Study: 30228027

Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAS-102
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Number of subjects: 0
Study: 27067836

Group type: EXPERIMENTAL
Intervention: Andrew's manoeuvre (four-hands CC) during DA-CPR
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (standard DA-CPR without Andrew's manoeuvre)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Female intervention group (with Andrew's manoeuvre)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Female control group (without Andrew's manoeuvre)
Number of subjects: 68
Study: 25902891

Group type: EXPERIMENTAL
Intervention: Naloxone, opioid, and saline admixture (NOSA) containing 12 μg naloxone per 1 mg morphine per 1 mL normal saline.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group receiving morphine only.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Naloxone, opioid, and saline admixture (NOSA)
Number of subjects: 92
Study: 23043123

Group type: EXPERIMENTAL
Intervention: Sparklines
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Relative multigraphs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Absolute multigraphs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tables
Number of subjects: 20
Study: 21079814

Group type: EXPERIMENTAL
Intervention: Striatum activation during successful stopping
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Striatum activation proportional to left M1 deactivation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Striatum activation linked to stop-signal probability
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Striatum activation linked to SMC and rIFC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trial-to-trial variations in response time
Number of subjects: 24
Study: 18066530

Group type: EXPERIMENTAL
Intervention: Open repair (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Percutaneous repair with Tenolig (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both open and percutaneous techniques
Number of subjects: 40
Study: 16611287

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 1 microg/kg x min
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study: 14550427

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg/day) for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 80
Study: 10781643

Group type: EXPERIMENTAL
Intervention: Vitamin E 200 mg/day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg/day
Number of subjects: 37
Study: 9165857

Group type: EXPERIMENTAL
Intervention: Home support from a trained oncology nurse during treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visits after treatment
Number of subjects: 0
Study: 1492458

Group type: EXPERIMENTAL
Intervention: 200 IE EPO/kg 2 x/week i.v. over 3 weeks (group C)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 100 IE EPO 2 x/week i.v. over 3 weeks (group B)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 82
Study: 3927958

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg thrice daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nicardipine 40 mg thrice daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31945816

Group type: EXPERIMENTAL
Intervention: GCWB104 (300 mg containing 125 mg of Flos Lonicera extract, twice daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (300 mg, twice daily)
Number of subjects: 92
Study: 30293770

Group type: EXPERIMENTAL
Intervention: LY3298176 (1 mg)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: LY3298176 (5 mg)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: LY3298176 (10 mg)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: LY3298176 (15 mg)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316

Group type: COMPARATOR
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Dulaglutide
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: LY3298176
Number of subjects: 316
Study: 26990722

Group type: EXPERIMENTAL
Intervention: Explosive-type strength training of the plantar flexors (2 days per week for 4 weeks, 3 sets of 10 repetitions lasting less than 1 second)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study: 24998258

Group type: EXPERIMENTAL
Intervention: Early renal replacement therapy
Number of subjects: 864

Group type: COMPARATOR
Intervention: Delayed renal replacement therapy
Number of subjects: 864
Study: 22051059

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 21088400

Group type: EXPERIMENTAL
Intervention: Relaxin (intravenous doses)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 19029516

Group type: EXPERIMENTAL
Intervention: Subcutaneous IGF-1 (0.05 mg/kg body weight, twice daily)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 16234008

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FSG) performance by examiners
Number of subjects: 50000
Study: 12805341

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 50
Study: 10827388

Group type: EXPERIMENTAL
Intervention: Local delivery of 5000 U heparin infused into the arterial wall
Number of subjects: 179

Group type: COMPARATOR
Intervention: Intraluminal delivery of 5000 U heparin administered to the coronary artery lumen
Number of subjects: 179
Study: 8846277

Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA) using morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous morphine infusion
Number of subjects: 30
Study: 8198941

Group type: COMPARATOR
Intervention: 1 mg kg‐1 intravenous lignocaine
Number of subjects: 27

Group type: COMPARATOR
Intervention: 1 mg kg‐1 intravenous lignocaine (fed)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 1 mg kg‐1 intravenous lignocaine (fasted)
Number of subjects: 27
Study: 3332678

Group type: EXPERIMENTAL
Intervention: Topical benzyl alcohol (BA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Catalin
Number of subjects: 0
Study: 29030160

Group type: EXPERIMENTAL
Intervention: Mobile application (PBAC app)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Paper diary (PBAC)
Number of subjects: 25
Study: 27321610

Group type: EXPERIMENTAL
Intervention: Memory-encoding strategy ("If I see Cue X, then I will perform Intention Y")
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard encoding condition
Number of subjects: 72
Study: 26358690

Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renal function assessment methods (iohexol clearance, Cockcroft-Gault, MDRD)
Number of subjects: 0
Study: 23587538

Group type: EXPERIMENTAL
Intervention: Standardized uterosacral ligament suspension colpopexy (USLSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no USLSC)
Number of subjects: 0